At the International Myotonic Dystrophy Consortium this week, Domi Stickens, PhD, Chief Scientific Officer, presents a poster on our RNA-targeted small-molecule therapeutics and the first oral therapy in development for myotonic dystrophy type 1 (DM1).
#IDMC15 #MyotonicDystrophy #ArrakeensInAction